Roche on Monday joined AstraZeneca in withdrawing cancer immunotherapies from U.S. use for bladder cancer that has already been treated with platinum-based chemotherapy, after follow-up studies failed to meet goals. Basel-based Roche said in a statement it was withdrawing the U.S. indication for Tecentriq, with some $3 billion in 2020 sales, in prior-platinum treated metastatic urothelial carcinoma. In February, AstraZeneca announced a similar move for its $2 billion-per-year drug Imfinzi.
Covid 19 coronavirus: Sir Brian Roche, Rob Fyfe among team brought in to oversee review of NZ s pandemic response
8 Mar, 2021 08:39 PM
4 minutes to read
Covid-19 Response Minister Chris Hipkins during the post-Cabinet press conference at Parliament, Wellington. 08 March, 2021. Photo / Mark Mitchell
Jason Walls is a political reporter for the New Zealand Heraldjason.walls@nzme.co.nz@Jasonwalls92
The Government has appointed a special advisory group, led by business executive Sir Brian Roche, to help ensure it learns and adapts when it comes to the Covid-19 Response.
Former Air NZ chief executive Rob Fyfe is also on the new group.
In a statement this morning, Covid-19 Response Minister Chris Hipkins said this new advisory group would formalise its ongoing approach to independent review and improvement around Covid-19.
Blockbuster Roche drug Tecentriq will be pulled from the U.S. market as a bladder cancer treatment three years after failing clinical tests required to stay on the market. The voluntary withdrawal comes amid an industry-wide FDA review of drugs that were awarded accelerated approval but later failed confirmatory studies.
Mar 5, 2021 11:20am
Roche s Actemra has become the first biologic that the FDA approved for patients with systemic sclerosis-associated interstitial lung disease. (Roche/Genentech)
Missed the primary endpoint of a clinical trial? No problem. We’ll pick the study apart and approve your drug based on a post-hoc subgroup analysis.
That’s what the FDA did in granting Roche’s Actemra a go-ahead in patients with interstitial lung disease (ILD) associated with the rare autoimmune disease systemic sclerosis (SSc).
The approval makes Actemra the first biologic drug cleared by the FDA to slow the decline in pulmonary function in patients with SSc-ILD, Roche’s Genentech said Thursday.
Animal Crossing: New Horizons: lista con todos los peces de marzo vidaextra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vidaextra.com Daily Mail and Mail on Sunday newspapers.